These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20686744)

  • 1. The botulinum neurotoxin LD50 test - problems and solutions.
    Bitz S
    ALTEX; 2010; 27(2):114-6. PubMed ID: 20686744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin testing on animals is still a Europe-wide issue.
    Taylor K; Gericke C; Alvarez LR
    ALTEX; 2019; 36(1):81-90. PubMed ID: 30303513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting.
    Adler S; Bicker G; Bigalke H; Bishop C; Blümel J; Dressler D; Fitzgerald J; Gessler F; Heuschen H; Kegel B; Luch A; Milne C; Pickett A; Ratsch H; Ruhdel I; Sesardic D; Stephens M; Stiens G; Thornton PD; Thürmer R; Vey M; Spielmann H; Grune B; Liebsch M
    Altern Lab Anim; 2010 Aug; 38(4):315-30. PubMed ID: 20822324
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro potency determination of botulinum neurotoxin serotype A based on its receptor-binding and proteolytic characteristics.
    Behrensdorf-Nicol HA; Wild E; Bonifas U; Klimek J; Hanschmann KM; Krämer B; Kegel B
    Toxicol In Vitro; 2018 Dec; 53():80-88. PubMed ID: 30016653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A.
    Hunt T; Clarke K
    Clin Neuropharmacol; 2009; 32(1):28-31. PubMed ID: 18978494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
    Adler M; Keller JE; Sheridan RE; Deshpande SS
    Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growing old disgracefully: the cosmetic use of botulinum toxin.
    Bottrill K
    Altern Lab Anim; 2003 Sep; 31(4):381-91. PubMed ID: 15601243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6.
    Moritz MS; Tepp WH; Bradshaw M; Johnson EA; Pellett S
    mSphere; 2018 Oct; 3(5):. PubMed ID: 30355669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in applying the Three Rs to the potency testing of Botulinum toxin type A.
    Straughan D
    Altern Lab Anim; 2006 Jun; 34(3):305-13. PubMed ID: 16831062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent developments on the European ban on animal experiments for cosmetics].
    Ruhdel IW
    ALTEX; 2001; 18(1):13-6. PubMed ID: 11248844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of sensitive colorimetric capture ELISAs for Clostridium botulinum neurotoxin serotypes E and F.
    Poli MA; Rivera VR; Neal D
    Toxicon; 2002 Jun; 40(6):797-802. PubMed ID: 12175617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
    Wortzman MS; Pickett A
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A quantitative bifunctional in vitro potency assay for botulinum neurotoxin serotype A.
    Gregory RW; Werner WE; Ruegg C
    J Pharmacol Toxicol Methods; 2014; 69(2):103-7. PubMed ID: 24333955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A substrate sensor chip to assay the enzymatic activity of Botulinum neurotoxin A.
    Lévêque C; Ferracci G; Maulet Y; Grand-Masson C; Blanchard MP; Seagar M; El Far O
    Biosens Bioelectron; 2013 Nov; 49():276-81. PubMed ID: 23787358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin.
    Sesardic D; Leung T; Gaines Das R
    Biologicals; 2003 Dec; 31(4):265-76. PubMed ID: 14624797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells.
    Wang L; Sun Y; Yang W; Lindo P; Singh BR
    Toxicon; 2014 May; 82():52-60. PubMed ID: 24560879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin.
    Huang NJ; Pishesha N; Mukherjee J; Zhang S; Deshycka R; Sudaryo V; Dong M; Shoemaker CB; Lodish HF
    Nat Commun; 2017 Sep; 8(1):423. PubMed ID: 28871080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An innovative molecular detection tool for tracking and tracing Clostridium botulinum types A, B, E, F and other botulinum neurotoxin producing Clostridia based on the GeneDisc cycler.
    Fach P; Fenicia L; Knutsson R; Wielinga PR; Anniballi F; Delibato E; Auricchio B; Woudstra C; Agren J; Segerman B; de Medici D; van Rotterdam BJ
    Int J Food Microbiol; 2011 Mar; 145 Suppl 1():S145-51. PubMed ID: 20471128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.
    Broide RS; Rubino J; Nicholson GS; Ardila MC; Brown MS; Aoki KR; Francis J
    Toxicon; 2013 Sep; 71():18-24. PubMed ID: 23707612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Globular chitosan prolongs the effective duration time and decreases the acute toxicity of botulinum neurotoxin after intramuscular injection in rats.
    Sergeevichev DS; Krasilnikova AA; Strelnikov AG; Fomenko VV; Salakhutdinov NF; Romanov AB; Karaskov AM; Pokushalov EA; Steinberg JS
    Toxicon; 2018 Mar; 143():90-95. PubMed ID: 29371111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.